Navigation Links
Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM
Date:3/19/2012

FORT LAUDERDALE, Fla., March 19, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that Advent Financial, a leading financial analyst group focused on small and micro-cap companies, estimated next 5-year revenue for the Company at $42MM.  Advent has a very qualified team of research analysts with extensive experience at large investment banks including Bank of America, Goldman Sachs, and UBS Warburg.

As published in the analyst report in the projections and valuation section, Advent estimated next 5-year revenue for the Company at $42MM using the following assumptions: a) Company will steadily increase its distribution footprint by signing agreements with national pharmacy chains; b) Over the next five years, Azul Instant™ will be available at 35% of all retail outlets managed by the national pharmacy chains.  Agreements with traditional retailers will provide further upside to our revenue estimate; c) Average revenue per store will increase from $300/month in 2012 to $500/month by 2013.

To view the report in its entirety, please visit: http://www.adventfinancialinc.com/research/index.php under recent reports.

About Azul Instant™

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals to provide a safe and natural alternative for the millions of men suffering from erectile dysfunction.  The Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated.  Patients will now receive the NATURAL benefits of Azul Instant™ and unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects.  While there are ot
'/>"/>

SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants
2. Leading Cardiovascular Organizations Release Credentialing Recommendations for Heart Valve Replacement Procedure
3. Qmed, the Leading Global MedTech Industry Resource, Partners with onTargetjobs to Provide Medical Device Professionals and Employers with Career Services Tool
4. Leading Industry Multinationals Participate in Medical Device Costa Rica Panel: "Developing a Strong Supplier Base"
5. Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Companys Market Leading Position
6. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
7. Leading Antitrust Senator Raises Serious Doubts About Proposed Express Scripts-Medco PBM Merger
8. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
9. Worlds Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event
10. Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
11. International Panel of Leading Bariatric Surgeons Reaches Consensus on Optimal Techniques for Laparoscopic Sleeve Gastrectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... leading,developer of medical simulation systems, today announced an agreement ... and related,products. , Johnson & ... and,is one of the subsidiaries of Johnson & Johnson. ... will have exclusive rights to distribute,Simbionix,s line of advanced ...
... Newly Diagnosed Patients Receive a Drug Within One Year ... from Decision ResourcesWALTHAM, Mass., April 15 /PRNewswire/ ... leading research and advisory firms focusing on pharmaceutical and ... than 30 percent of their use of emerging oral ...
Cached Medicine Technology:Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... 2008 -- Women born after 1944 began drinking alcohol at ... put them at greater risk for alcoholism, according to researchers ... On average, women born before 1944 began drinking at age ... 17, and they had a 50 to 80 percent greater ...
... and ... Launch in Spanish, CHICAGO and ... in health education, and Merck & Co.,Inc., a global research-driven pharmaceutical ... multi-year relationship,to transform how healthcare professionals engage patients in learning about,diabetes ...
... June 5 Nuvelo, Inc.,(Nasdaq: NUVO ) ... the,company,s Wnt Therapeutics program showing that the R-spondin ... pathway that is critical for,cell growth and differentiation ... the activity of Wnt proteins, and,modulated the Wnt ...
... FALLS CHURCH, Va., June 5 CSC (NYSE: ... LLC (DVC), a CSC company, has been,notified by ... funding for,advanced development of plague vaccine will be ... Project Manager Chemical, Biological and,Medical Systems, Joint Vaccine ...
... of alcohol a week can trim that risk by 50%, ... who drink alcohol regularly may cut their risk of developing ... been shown to reduce the risk of cardiovascular disease, and ... risk of rheumatoid arthritis by up to 50 percent. This ...
... LEAN CUISINE(R) are Nutritious and Delicious, SOLON, Ohio, ... know they,re good for us and want to reap ... how to incorporate them into,convenient and tasty meals. A ... benefits of the Omega-3 fatty acids DHA and,EPA. These ...
Cached Medicine News:Health News:Initiating drinking at younger age heightens women's risk for alcohol dependence 2Health News:Initiating drinking at younger age heightens women's risk for alcohol dependence 3Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 2Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 3Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 4Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 3Health News:CSC's DynPort Vaccine Company to Continue Plague Vaccine Development 2Health News:CSC's DynPort Vaccine Company to Continue Plague Vaccine Development 3Health News:Drinking Cuts Rheumatoid Arthritis Risk 2Health News:Drinking Cuts Rheumatoid Arthritis Risk 3Health News:Now You Can Have Your Fish and Enjoy It Too... 2Health News:Now You Can Have Your Fish and Enjoy It Too... 3
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
Medicine Products: